New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Abstract

Abstract Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Keywords

• bisphosphonate‐associated osteonecrosis
• ipilimumab
• medically compromised patients
• medication‐related osteonecrosis of the jaw
• target therapy